Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Alembic Pharmaceuticals receives USFDA final approval for Dapsone Gel
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dapsone Gel, 5%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Aczone Gel, 5%, of Almirall, LLC.
Vikran Engineering secures solar power projects worth Rs 3,517.98
Vikran Engineering said that it has accepted a turnkey EPC work order worth Rs 3,517.98 crore from NOPL Solar Projects for the development of a 969 MW AC solar power project across multiple locations in Maharashtra.
Homebuyer can seek compensation for delayed delivery after taking possession: SC
Homebuyers can pursue compensation for delayed flat delivery even after taking possession, the Supreme Court ruled. The apex court overturned a previous order that denied a buyer's consumer status post-possession. The court emphasized that a claim for delayed possession arises before delivery and subsequent acceptance doesn't negate the right to seek adjudication. The case was sent back for a decision on merits.
IIT Bombay, New York University announce collaboration in engineering education, research
IIT Bombay has teamed up with the State University of New York Old Westbury to enhance education and research in science and engineering. This partnership will delve into cutting-edge areas like artificial intelligence, aiming to establish collaborative programs and research projects.
Bajaj Healthcare secures SEC recommendation for Cenobamate tablets
Bajaj Healthcare announced that Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO) has recommended for grant of approval for manufacturing and marketing of Cenobamate Tablets.
OpenAI's GPT-5.6 Is Here: What's New And Why Is It Restricted To US?
OpenAI said it ultimately intends to make GPT-5.6 Sol, Terra and Luna available across ChatGPT, the API and Codex in the coming weeks, adding that it does not believe government preview requirements should become the long-term standard for frontier AI releases.
Puravankara clears ₹145 crore sale of subsidiary to ICICI Prudential AIF-backed entity
On Thursday (June 25), shares of Puravankara Ltd ended at ₹214.15, down by ₹0.60, or 0.28%, on the BSE.
Transrail Lighting Ltd secures overseas orders worth Rs 459 cr
Transrail Lighting Ltd has secured significant international orders totaling approximately Rs 459 crore, primarily for transmission line construction in the Middle East and North Africa. This boosts the company's total order inflow for the year to Rs 1,034 crore. Additionally, Transrail is the Lowest (L1) bidder for projects worth around Rs 400 crore, indicating a strong future pipeline and sustained growth prospects.
Indian refiners unlikely to rush for Iranian oil despite temporary US sanctions waiver, says analyst
Indian refiners are unlikely to sharply raise purchases of Iranian crude despite a 60-day US sanctions waiver, as uncertainty over its duration, payment hurdles and existing supply commitments limit fresh buying, market analyst Sumit Ritolia said. Refiners have already secured most crude requirements for the coming months through advance procurement plans.
BEML secures additional export order worth USD 5.35 million from West Asia
BEML Ltd has secured a significant USD 5.35 million export order for heavy earthmoving equipment from West Asia, building on a previous USD 36.38 million contract. These robust machines, designed for demanding mining and infrastructure projects, boast advanced engineering and operator safety features. BEML will also provide comprehensive maintenance and lifecycle support, underscoring their commitment to global customer satisfaction and expanding their international presence.
Alembic Pharma gets USFDA nod for generic influenza treatment drug
Alembic Pharmaceuticals has secured USFDA approval for its generic oseltamivir phosphate oral suspension, a key treatment for influenza. This development offers a more accessible option for patients aged two weeks and above suffering from acute, uncomplicated flu. The approval marks a significant step in providing affordable alternatives to the reference drug, Tamiflu, potentially impacting a market valued at an estimated USD 27 million.
Alembic Pharma gets USFDA nod for generic Tamiflu oral suspension
Alembic Pharmaceuticals' cumulative USFDA approvals now stand at 243 ANDAs, comprising 223 final approvals and 20 tentative approvals.